Karuna Therapeutics, Inc.
KRTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.79 | -0.29 | -0.29 | 1.27 |
| FCF Yield | -3.32% | -3.68% | -2.72% | -2.62% |
| EV / EBITDA | -23.38 | -20.62 | -25.27 | -38.48 |
| Quality | ||||
| ROIC | -38.99% | -25.73% | -28.23% | -21.04% |
| Gross Margin | -160.09% | 89.55% | 98.63% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.83 | 0.70 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -73.94% | – | – | – |
| Free Cash Flow Growth | -69.81% | -120.22% | -47.92% | -126.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.34 | 0.84 | 1.39 | 0.74 |
| Interest Coverage | 0.00 | -20.43 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.05 | 0.04 | 0.02 | 0.00 |
| Cash Conversion Cycle | 8,324.08 | 8,518.40 | 13,683.86 | -2,177.41 |